Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Seres Therapeutics FY GAAP EPS $(0.89) Beats $(0.96) Estimate, Sales $126.33M Beat $126.07M Estimate

Author: Benzinga Newsdesk | March 05, 2024 08:04am
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(0.96) by 7.29 percent. This is a 61.47 percent increase over losses of $(2.31) per share from the same period last year. The company reported quarterly sales of $126.33 million which beat the analyst consensus estimate of $126.07 million by 0.21 percent. This is a 1.67K percent increase over sales of $7.13 million the same period last year.

Posted In: MCRB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist